Enzolytics Inc (ENZC)

[OTCShotCaller]

Many of you may be interest in learning about a parallel rival to Enzolytics-Bioclonetics I was discussing today with an Immunologist colleague of mine from the BigPharma Industry.

During our discussion, I mentioned that Endolytics-BioClonetics is currently in the process of merging, and that post-merger as one company, they will collaborate to bring the Clone-3 Monoclonal Ab to market for curative treatment of 95% of AIDS/HIV strains. We discussed the various immunological implications of this as an effective treatment for HIV.

When I mentioned this, he was very surprised and also not familiar with Enzolytics or BioClonetics. However he informed me that a Company by the name of CytoDyne has a proprietary patent on a laboratory engineered monoclonal antibody by the name of Leronlimab (P140) they're developing for commercialization for HIV & Covid-19 treatment that follows the basic Mechanism of Action as BioClonetic's Clone-3 Ab., i.e. it binds to the surface of cells preventing the entry of the HIV virus.

CytoDyne's antibody apparently is a "humanized" form of the naturally occurring antibody by the name of Leronlimab (P 140). However, looking into this further CytoDyne reveals that their Phase-III trials of Leonlimab (P-140) have only been effective in moderate suppression of viral load, and it has NOT been identified as being effective in all known stains of HIV Virus sub-types of which there are at least 89. So far it appears that they're treating only HIV-1, NOT HIV-2, and NOT any of the associated HIV sero-type sub-classes.

Also, this therapy requires daily combined doses of the HIV standard treatment protocol known as Anti-Retro-Viral (A.R.T.) drug therapy in tandem. Therefore, it's NOT Monotherapy like BioClonetics Clone 3 Ab; a major difference. This is also in contrast to Clonetics Clone-3 being effective in up to 95% of all known HIV primary class and sub-types.

More specifically, CytoDyn’s Leronlimab (PRO 140) monoclonal antibody, is a humanized "IgG-4 mAb" that blocks CCR5, a cellular receptor that has a role not only with HIV infection, but also in tumor metastases and immune signaling. I researched this on CytoDyne's website and discovered they have successfully completed nine Phases 1-3 clinical trials, including a successful pivotal Phase 3 trial in combination with standard anti-retroviral therapies in HIV-infected patients. Overall, there at least 64 Monoclonal Antibodies in existence that have been developed into drug therapies for treating various diseases.

Apparently what CytoDyne has with its Leronlimab (P140) is so promising based on their preliminary trials, they've been granted FDA Approval for fast-track development for treating HIV, and Emergency Development for treating Covid-19.

https://www.drugs.com/history/leronlimab.html


So CytoDyne is well on its way to commercialization of Leronlimab (P140) for treating HIV, Covid-19, and several others diseases, and like Enzolytics, they're trading on the OTC under the symbol: CYDY with a share price of $3.27 as of Friday 10/9/20 close of market.

I mention this last point because it reveals that although this company has NO products on the market and no revenues, their stock PPS is currently trading in the $3 range. Within the past 52-Weeks it had a trading range of $0.52-$10.00. My point here is they got their start NO DIFFERENT than Enzolytics-BioClonetics as an HIV drug development company listed on the OTC, and I discover that prior to the past 52 Weeks, they were trading at a low of $0.16. It's interesting to note that CytoDyne's share price rose to $0.42 upon announcement they partnered into a commercialization and license agreement with Vyera Pharmaceuticals LLC who holds the Patent on Leronlimbab (PRO 140) to commercialize it in the U.S. for HIV treatment. From there, within less than a year CytoDyne's PPS rose to as high as $10. (take a look at it's trading history).

Relative this partnership, CytoDyne will be responsible for the development and FDA approval of leronlimab (PRO-140) for HIV treatment including related indications, while Vyera will have exclusive license to market and distribute leronlimab (P140) in the U.S. Additionally, Vyera has agreed to pay upfront regulatory and sales-based milestone payments of up to $87.5 Million, as well as a royalty of 50% on net sales to CytoDyne. Furthermore, Vyera also agreed to purchase $4 Million of Cytodyne's stock.

Here's the links to:

1), CytoDyne: https://www.cytodyn.com

2). Vyera Pharmaceuticals: https://www.vyera.com

3). CytoDyne & Vyera Pharmaceuticals partnership arrangements that just took place 10-Months ago in December 2019:

https://www.globenewswire.com/news-release/2019/12/17/1961907/0/en/CytoDyn-Signs-Definitive-Agreements-with-Vyera-Pharmaceuticals-to-Commercialize-Leronlimab-in-the-U-S-for-the-Treatment-of-HIV.html

4). CytoDyne engaged in application of their Leronlimab (P-140) for treating Covid-19

https://www.cytodyn.com/newsroom/press-releases/detail/453/update---impressive-results-from-cytodyns-phase-2

https://www.sec.gov/Archives/edgar/data/1175680/000119312520004683/d855842dex105.htm

5), CytoDyne's Proproetary Leronlimab (PRO-140): https://en.wikipedia.org/wiki/PRO_140

6). CytoDyne's Stock Soars After Partnering with Vyera Pharmaceuticals:

https://www.proactiveinvestors.com/companies/news/909402/cytodyn-soars-after-partnering-with-vyera-pharmaceuticals-to-commercialize-leronlimab-in-us-to-treat-hiv-909402.html

It's probably obvious by now I'm contrasting forward looking developments with Enzolytics-BioClonetics relative to what happened between CytoDyne & Vyera Pharmaceuticals, keeping in mind that CytoDyne's stock pps rose very quickly upon news of their official partnership. I believe the same thing will happen post-merger of Enzolytics & BioClonetics, and again, when they contract out the commercialization of their Clone-3 Ab with a Major BigPharma player that has the infrastructure and resources to make it happen.

I believe they follow a similar pattern coming into the pharmaceutical marketplace. The question remains however, that upon post-merger into one company, who will they seek out as a partner developer of their Clone 3 technology to bring their product to commercialization? I believe by far they have a superior Monoclonal Antibody technology for treating HIV Virus and related infectious disease viruses including Covid-19, compared to CytoDyne-Vyera.

So CytoDyne is well on its way to commercialization of Leronlimab (P140) for treating HIV, Covid-19, and several others diseases, and like Enzolytics, they're trading on the OTC under the symbol: CYDY with a share price of $3.27 as of Friday 10/9/20 close of market.

I mention this last point because it reveals that although this company has NO products on the market and no revenues, their stock PPS is currently trading in the $3 range. Within the past 52-Weeks it had a trading range of $0.52-$10.00. My point here is they got their start NO DIFFERENT than Enzolytics-BioClonetics as an HIV drug development company listed on the OTC, and I discover that prior to the past 52 Weeks, they were trading at a low of $0.16. It's interesting to note that CytoDyne's share price rose to $0.42 upon announcement they partnered into a commercialization and license agreement with Vyera Pharmaceuticals LLC who holds the Patent on Leronlimbab (PRO 140) to commercialize it in the U.S. for HIV treatment. From there, within less than a year CytoDyne's PPS rose to as high as $10. (take a look at it's trading history).

Relative to the terms of this partnership, CytoDyn will be responsible for the development and FDA approval of leronlimab (PRO-140) for HIV treatment including related indications, while Vyera will have exclusive license to market and distribute leronlimab (P140) in the U.S.

Additionally, Vyera has agreed to pay upfront regulatory and sales-based milestone payments of up to $87.5 Million, as well as a royalty of 50% on net sales to CytoDyne. Furthermore, Vyera also agreed to purchase $4 Million of Cytodyne's stock.

Here's the links to:

1), CytoDyne: https://www.cytodyn.com

2). Vyera Pharmaceuticals: https://www.vyera.com

3). CytoDyne & Vyera Pharmaceuticals partnership arrangements that just took place 10-Months ago in December 2019:

4). CytoDyne engaged in application of their Leronlimab (P-140) for treating Covid-19

https://www.cytodyn.com/newsroom/press-releases/detail/453/update---impressive-results-from-cytodyns-phase-2

https://www.globenewswire.com/news-release/2019/12/17/1961907/0/en/CytoDyn-Signs-Definitive-Agreements-with-Vyera-Pharmaceuticals-to-Commercialize-Leronlimab-in-the-U-S-for-the-Treatment-of-HIV.html

https://www.sec.gov/Archives/edgar/data/1175680/000119312520004683/d855842dex105.htm

5), CytoDyne's Proproetary Leronlimab (PRO-140): https://en.wikipedia.org/wiki/PRO_140

6). CytoDyne's Stock Soars After Partnering with Vyera Pharmaceuticals:

https://www.proactiveinvestors.com/companies/news/909402/cytodyn-soars-after-partnering-with-vyera-pharmaceuticals-to-commercialize-leronlimab-in-us-to-treat-hiv-909402.html

It's probably obvious by now I'm contrasting forward looking developments with Enzolytics-BioClonetics relative to what happened between CytoDyne & Vyera Pharmaceuticals, keeping in mind that CytoDyne's stock pps rose very quickly upon news of their official partnership. I believe the same thing will happen post-merger of Enzolytics & BioClonetics, and again, when they contract out the commercialization of their Clone-3 Ab with a Major BigPharma player that has the infrastructure and resources to make it happen.

I believe they follow a similar pattern coming into the pharmaceutical marketplace. The question remains however, upon post-merger into one company, who will they seek out as a partner developer of their Clone 3 technology to bring their product to commercialization? I believe by far they have a superior Monoclonal Antibody technology for treating HIV Virus and related infectious disease viruses including Covid-19, compared to CytoDyne-Vyera.

I hope this review was of interest to everyone.

Be well and prosper .....